preventing alzheimer disease-related gray matter atrophy b-vitamin treatment abstract prevent atrophy key brain regions related cognitive decline alzheimer disease ad approach modify nongenetic risk factors instance lowering elevated plasma homocysteine vitamins initial randomized controlled study elderly subjects increased dementia risk mild cognitive impairment num petersen criteria showed high-dose b-vitamin treatment folic acid num mg vitamin num mg vitamin num num mg slowed shrinkage brain volume num demonstrating b-vitamin treatment reduces fold cerebral atrophy gray matter gm regions specifically vulnerable ad process including medial temporal lobe placebo group higher homocysteine levels baseline faster gm atrophy deleterious effect largely prevented b-vitamin treatment additionally show beneficial effect vitamins confined participants high homocysteine median num mol/l participants causal bayesian network analysis chain events vitamins lower homocysteine directly leads decrease gm atrophy slowing cognitive decline results show b-vitamin supplementation slow atrophy specific brain regions key component ad process cognitive decline b-vitamin supplementation trials focusing elderly subjets high homocysteine levels warranted progression dementia prevented 
